NSCLC非经典EGFR突变患者临床特点及治疗预后分析

目的 了解表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)对非经典突变非小细胞肺癌(non-small-cell lung cancer,NSCLC)的治疗疗效,为非经典突变患者选择最合适的靶向药物...

Clinical characteristics and prognosis of non-classical mutations of epidermal growth factor receptor in non-small-cell lung cancer

Objective: To understand the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of non-small-cell lung cancer (NSCLC) patients with non-classical mutations, so as to provide a reference for NSCLC patients with non-classical mutations to select the most appropriate target drugs. Methods: NSCLC patients with EGFR non-classical mutations were collected, and the clinical characteristics were analyzed. The treatment effects of 29 patients receiving tyrosine kinase inhibitor (TKI) were analyzed. Results: There were no statistically significant differences in sex, age, smoking history and pathological stage between 39 patients with single mutation and 17 patients with double mutations (all P>0.05). For those treated with TKI, the objective response rate (ORR) was 34.5%, the disease control rate (DCR) was 75.9%, and the median progression-free survival (mPFS) was 8 months. There was no statistically significant difference in mPFS between patients with single mutation and double mutations (7 months vs 9 months, P=0.173), and there was a statistically significant difference in mPFS between patients treated with first-generation TKI drugs (n=19) and those treated with second-generation TKI drugs (n=10; 6 months vs 9.5 months, P=0.011). Conclusions: For NSCLC patients receiving EGFR-TKI treatment,the second-generation TKI may be more suitable for the treatment of those with non-classical mutation. Whether the efficacy of patients with double mutations is better than that of patients with single mutation should be verified in a larger sample size study. © 2021, The Second Affiliated Hospital, College of Medicine, Zhejiang University.. All right reserved.